Health Economics & HTA Insights

Articles on health technology assessment, cost-of-illness analysis, QALYs, and market access strategy for pharmaceutical companies in the MEA region.

Health Economics
The Four Pillars of Market Access: Turning Innovation into Patient Impact
Regulatory approval may open the door, but it does not guarantee that a therapy will be funded, adopted, or used at scale. How the four pillars of market access turn innovation into access, adoption, and long-term value for patients and payers.
July 27, 2026 · 4 min read
Health Economics
When Every Year Counts: QALY and evLYG in Modern Health Evaluation
Clinicians work to help individual patients choose the best treatment for their personal needs. In contrast, cost-effectiveness analysis looks at evidence for...
October 25, 2025 · 3 min read
Health Economics
The Role of HTA in Breast Cancer: Driving Value in Diagnostics and Drug Evaluation
Health Technology Assessment (HTA) has become the backbone of evidence-informed decision-making in oncology, ensuring that innovative diagnostics and...
August 15, 2025 · 3 min read
Health Economics
From Burden to Value: The Strategic Importance of Cost-of-Illness Analysis in HTA
Cost-of-illness (COI) analysis is a foundational economic evaluation in healthcare. It measures the total economic burden of illness on society. The primary...
September 16, 2024 · 2 min read
Health Economics
Evidence-Based Decisions in Pharma & Healthcare: The Stellar Approach
In today’s rapidly evolving healthcare landscape, decision-making is no longer driven by intuition or isolated data points. From R&D to market access, policy...
August 11, 2024 · 5 min read

Health Economics & HTA Insights — Stellar Consulting